AU2022368026A1 - Antibody or fragment thereof binding specifically to mertk, and anti-tumor agent - Google Patents

Antibody or fragment thereof binding specifically to mertk, and anti-tumor agent Download PDF

Info

Publication number
AU2022368026A1
AU2022368026A1 AU2022368026A AU2022368026A AU2022368026A1 AU 2022368026 A1 AU2022368026 A1 AU 2022368026A1 AU 2022368026 A AU2022368026 A AU 2022368026A AU 2022368026 A AU2022368026 A AU 2022368026A AU 2022368026 A1 AU2022368026 A1 AU 2022368026A1
Authority
AU
Australia
Prior art keywords
amino acid
seq
acid sequence
antibody
mertk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022368026A
Other languages
English (en)
Inventor
Toshikazu Inoue
Hiroaki Kambayashi
Atsushi Sawada
Aki TAKESUE
Masayoshi Toyoura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiome Bioscience Inc
Original Assignee
Chiome Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiome Bioscience Inc filed Critical Chiome Bioscience Inc
Publication of AU2022368026A1 publication Critical patent/AU2022368026A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2022368026A 2021-10-15 2022-09-16 Antibody or fragment thereof binding specifically to mertk, and anti-tumor agent Pending AU2022368026A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021169289 2021-10-15
JP2021-169289 2021-10-15
PCT/JP2022/034801 WO2023063026A1 (ja) 2021-10-15 2022-09-16 ＭｅｒＴＫに特異的に結合する抗体又はその断片、及び抗腫瘍剤

Publications (1)

Publication Number Publication Date
AU2022368026A1 true AU2022368026A1 (en) 2024-05-02

Family

ID=85987671

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022368026A Pending AU2022368026A1 (en) 2021-10-15 2022-09-16 Antibody or fragment thereof binding specifically to mertk, and anti-tumor agent

Country Status (9)

Country Link
US (1) US20250326862A1 (https=)
EP (1) EP4417625A4 (https=)
JP (1) JPWO2023063026A1 (https=)
KR (1) KR20240082341A (https=)
CN (1) CN118215684A (https=)
AU (1) AU2022368026A1 (https=)
CA (1) CA3233968A1 (https=)
IL (1) IL311952A (https=)
WO (1) WO2023063026A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7211703B2 (ja) * 2014-12-22 2023-01-24 ザ ロックフェラー ユニバーシティー 抗ｍｅｒｔｋアゴニスト抗体及びその使用
WO2020076799A1 (en) * 2018-10-09 2020-04-16 Bristol-Myers Squibb Company Anti-mertk antibodies for treating cancer
BR112021020867A2 (pt) * 2019-04-19 2022-01-04 Genentech Inc Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração
JP2023506465A (ja) * 2019-12-13 2023-02-16 アレクトル エルエルシー 抗ＭｅｒＴＫ抗体及びその使用方法

Also Published As

Publication number Publication date
CN118215684A (zh) 2024-06-18
EP4417625A1 (en) 2024-08-21
IL311952A (en) 2024-06-01
EP4417625A4 (en) 2026-01-14
CA3233968A1 (en) 2023-04-20
WO2023063026A1 (ja) 2023-04-20
JPWO2023063026A1 (https=) 2023-04-20
US20250326862A1 (en) 2025-10-23
KR20240082341A (ko) 2024-06-10

Similar Documents

Publication Publication Date Title
TWI894157B (zh) 包含血管舒緩素相關肽酶２抗原結合域之蛋白質及其用途
AU2024205621A1 (en) Humanized antibodies against c-Kit
US10233258B2 (en) Bispecific binding proteins that bind CD40 and mesothelin
JP2026021379A (ja) 新規抗ｌｉｌｒｂ４抗体および派生産物
RU2668170C2 (ru) Анти-в7-н3-антитело
CA3070774A1 (en) B7-h4 antibodies and methods of use thereof
JP2020504101A (ja) 抗ｏｘ４０抗体及びそれらの使用
TW202210521A (zh) 對cd19具專一性之抗體及嵌合抗原受體
US20240392024A1 (en) Anti-tnfr2 monoclonal antibody and application thereof
JP2021513848A (ja) Ｌａｇ３に結合する治療用分子
TW202041537A (zh) 針對lag-3之工程化抗體及自其製備之雙特異性pd-1/lag-3結合蛋白
JP2021520201A (ja) 抗ｃｄ２７抗体およびその使用
TWI896517B (zh) 雙專一性抗體及製造與使用其的方法
AU2023412611A1 (en) Novel anti-gprc5d antibody
AU2022341443A1 (en) Anti-human cd3 antibody and use thereof
AU2022389530A1 (en) Bispecific antibody against tigit and pd-l1, and pharmaceutical composition thereof and use thereof
AU2025205131A1 (en) Therapeutic binding molecules
CN116635071A (zh) 抗tspan8-抗cd3双特异性抗体和抗tspan8抗体
TW202413442A (zh) 抗pd-1抗體減弱之il-2免疫結合物及其用途
AU2022368026A1 (en) Antibody or fragment thereof binding specifically to mertk, and anti-tumor agent
US20250326840A1 (en) BISPECIFIC ANTIBODY TARGETING SIRP-alpha AND PD-L1 OR ANTIGEN-BINDING FRAGMENT THEREOF AND USE
US20240327509A1 (en) Human cxcli6 antibodies and the use thereof
US20250346668A1 (en) Cd3-targeting antibody and use thereof
US20200087410A1 (en) Humanized anti-cd40 antibodies
AU2022355388A1 (en) Bispecific antibody and application thereof